Advances in scientific research suggest the possibility of a viable biosynthetic blood technology that could radically transform the health outcomes of people around the world. Such a development would enhance a drastically insufficient global supply of red blood cells needed for transfusions, while also mitigating severe risks to donor supply precipitated by future pandemic or environmental catastrophes. However, insufficient funding is obstructing necessary further development. There is a pressing need for focused investment to advance scientific development, and an opportunity for government and philanthropic funds to help ensure that safe, efficacious biosynthetic blood becomes commercializable in a manner that enables global affordable access.

“If you’re a woman or person of color, your health is being hurt by a lack of diversity in healthcare.”

RSV CEO Lindsay Androski celebrates a woman-led company that received FDA approval for a serious unmet need in women’s health, argues that more diverse leaders will increase industry focus on the needs of diverse patients, and talks about RSV’s efforts to address this issue through a first-of-its-kind program to train tomorrow’s diverse leaders in real-world drug development focused on unmet needs!

Stay tuned for another exciting announcement on that soon, as well as more details about RSV’s work to use existing technology to improve the lives of patients living with sickle cell disease.

The COVID-19 pandemic has underscored the importance of equitable distribution of vaccines and therapeutics for LMICs, and small-footprint manufacturing platforms that can be flexibly adapted to produce a wide variety of products and scaled to meet regional demand offer a compelling alternative to conventional pharmaceutical-manufacturing facilities.

Health Affairs Forefront published an article co-written by Andrew Spencer Goldman, RSV’s General Counsel & Head of Policy, about ways in which the NIH, the world’s most important funder of biomedical research, should approach global equitable access moving forward.

Nearly every philanthropist asks the same question when reviewing the impact of their giving: How can I do the most good for the most people?